Conference abstract · 9 Nov 2017
Conference abstractPublished 20 Nov 2013
Identification and characterization of annexin A1 as a clinically useful biomarker of responsiveness to PPARG ligand therapy in triple negative breast cancer
National University of Singapore, Singapore
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The basal-like breast cancer subtype is predominantly estrogen receptor (ER)-, progesterone receptor (PR)-, and C-erb B2 receptor (HER2)-negative, aptly named triple negative breast cancer (TNBC). TNBC lacks defined targeted therapies, and have unique molecular profile, aggressive behavior, distinct patterns of metastasis and, thereby, a poor clinical outcome. Tumors which belong to the basal subtype have a more aggressive clinical behavior when compared to those with a luminal phenotype and that 'basal' status may be an independent prognostic factor. Thus, identifying markers and therapeutic targets for TNBC is of pressing need. Our clinical data established basal and claudin-low subtypes of breast cancer (TNBC types) express significantly higher levels of annexin A1 (ANXA1) with poor survival outcome. Using model cell lines of TNBC, we observed a positive correlation between expression of ANXA1 and nuclear receptor, peroxisome proliferator-activated receptor gamma (PPARG). A similar correlation was also seen in clinical tissues. To establish if these two markers are indeed linked in TNBC, we show that expression of ANXA1 is induced by PPARG activation both in vitro and in vivo and has a predictive clinical value in determining chemo-sensitivity to PPARG ligands. Mechanistically, we established PPARG-induced ANXA1 protein interacts directly with RIP-1 leading to deubiquitination of RIP-1 thereby activating the death pathway. Since to date there are no published reports on PPARG-ANXA1 axis in RIP-1 induced death machinery in cancer, our study therefore provides new preclinical with mechanistic insight for the suitability of using baseline expression ANXA1 as one inclusion criteria for patient selection in future PPARG chemotherapy trials.
Subjects
BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 23 Mar 2015
Multiethnic triple negative breast cancer comparisons of gene expression shows enrichment of distinct pathways in ALDH1+ compared to CD44+/CD24-/EpCAM+ cancer stem cell populations
Conference abstract · 23 Mar 2015
Chemo-residual Triple-Negative Breast Tumor cells Exhibit Increased Metastatic Potential
Conference abstract · 4 Aug 2015
Isolation and characterization of circulating tumor cells (CTCs) in triple negative breast cancer patients in response to chemotherapy
Short communication · 31 Mar 2025
Molecular Biomarkers for Early Detection and Prognosis of Triple-Negative Breast Cancer: A Clinical Pathology Perspective
More from this journal
The newest in Journal of Cell Science & Therapy.
Perspective · 2 Feb 2026
Exploring Senescence and Its Influence on Tissue Function and Therapeutic Research
Commentary · 2 Feb 2026
Metabolism Regulation and Its Influence on Therapeutic Development in Human Disease
Commentary · 2 Dec 2025
Cellular Membranes and Transport Proteins as Regulators of Homeostasis and Metabolic Coordination
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Cell Science & Therapy
- SubjectBiology
- BylineArticles whose byline prints “Alan Prem Kumar”

